PerPAS: Topology-Based Single Sample Pathway Analysis Method
暂无分享,去创建一个
[1] Taesung Park,et al. Personalized identification of altered pathways in cancer using accumulated normal tissue data , 2014, Bioinform..
[2] Chris Sander,et al. The molecular diversity of Luminal A breast tumors , 2013, Breast Cancer Research and Treatment.
[3] Jos H Beijnen,et al. Clinical experience with aurora kinase inhibitors: a review. , 2009, The oncologist.
[4] Pooja Mittal,et al. A novel signaling pathway impact analysis , 2009, Bioinform..
[5] Chris T. A. Evelo,et al. WikiPathways: building research communities on biological pathways , 2011, Nucleic Acids Res..
[6] P. Schöffski,et al. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy , 2014, Leukemia.
[7] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..
[8] Linda Wordeman,et al. Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells , 2014, Nature Cell Biology.
[9] Jun Zhu,et al. Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. , 2013, Cancer discovery.
[10] Salvatore Pece,et al. TPT1/ TCTP-regulated pathways in phenotypic reprogramming. , 2013, Trends in cell biology.
[11] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[13] Christos Sotiriou,et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Barabasi,et al. Lethality and centrality in protein networks , 2001, Nature.
[15] P. C. de Witt Hamer,et al. WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe , 2011, Clinical Cancer Research.
[16] S. Schnitt,et al. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy , 2010, Modern Pathology.
[17] Michal Sheffer,et al. Pathway-based personalized analysis of cancer , 2013, Proceedings of the National Academy of Sciences.
[18] Chengyu Liu,et al. Identification of sample-specific regulations using integrative network level analysis , 2015, BMC Cancer.
[19] Sampsa Hautaniemi,et al. Integrative platform to translate gene sets to networks , 2010, Bioinform..
[20] Kenneth H. Buetow,et al. PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..
[21] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[22] Su-In Lee,et al. The Proteomic Landscape of Triple-Negative Breast Cancer. , 2015, Cell reports.
[23] G. Shapiro,et al. Aurora kinase inhibition as an anticancer strategy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Tim Beißbarth,et al. rBiopaxParser - an R package to parse, modify and visualize BioPAX data , 2013, Bioinform..
[25] Chad J Creighton,et al. The molecular profile of luminal B breast cancer , 2012, Biologics : targets & therapy.
[26] David Haussler,et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..
[27] Albert-László Barabási,et al. Error and attack tolerance of complex networks , 2000, Nature.
[28] T Park,et al. PATHOME: an algorithm for accurately detecting differentially expressed subpathways , 2014, Oncogene.
[29] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[30] Mark Gerstein,et al. The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..
[31] Channing J Der,et al. Oncogenic Activity of Ect2 Is Regulated through Protein Kinase Cι-mediated Phosphorylation* , 2010, The Journal of Biological Chemistry.
[32] K. Keyomarsi,et al. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. , 2010, Cancer research.
[33] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[34] Winston Haynes,et al. Differential Expression Analysis for Pathways , 2013, PLoS Comput. Biol..